News and Announcements
Imugene (AXS: IMU) Commences Phase 1b/2 Gastric Cancer Study, Receives Approvals to Initiate Clinical Trial & Secures Further Intellectual Property
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX: IMU), an immunoncology company is pleased to release its Appendix 4C for the quarter ended 30th June, 2017.
KEY TAKEAWAYS:
- Commenced the Phase 1b/2 gastric cancer study for HER-Vaxx
- Received full and final country regulatory approvals to initiate clinical trial;
- Commenced patient recruitment in all 8 clinical sites in Thailand, Taiwan and Hong Kong
- Secured further intellectual property for HER-Vaxx
- Completed further development of the next generation of mimotope targets and pipeline
- Commenced in vivo testing of arginine modulator in animal models of cancer
Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
